Similarly, a retrospective study by Senkal et al. (34) on 611 COVID-19 patients in Istanbul found that a total of 165 patients had severe disease (hospitalization for >14 days, ICU admission, or death), and the use ACEI was found to be significantly associated with lower disease severity [OR, 0.37 (95% CI 0.15–0.87)], milder infiltrations on CT, lower level of inflammatory markers (C-reactive protein and ferritin), and shorter hospital stay. This evidence concerns the gene CRP and COVID-19.